Halozyme Therapeutics (HALO) possesses solid growth attributes, which could help it handily outperfo

Canada Pension Plan Investment Board acquired a new position in shares of Halozyme Therapeutics, Inc

Freestone Grove Partners LP bought a new position in shares of Halozyme Therapeutics, Inc. (NASDAQ:

Does Halozyme Therapeutics (HALO) have what it takes to be a top stock pick for momentum investors?

HLF, HMC, MPC, HALO and GNW screen as high-earnings-yield value picks as inflation stays elevated.

Halozyme, Repligen, Iovance, Arcutis and Precigen have been highlighted in this Industry Outlook art

New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedica

NeoGenomics (NEO) is at a 52-week high, but can investors hope for more gains in the future? We take

Halozyme Therapeutics shares have appreciated over 80% since my initial coverage and investment in 2

Allworth Financial LP bought a new stake in Halozyme Therapeutics, Inc. (NASDAQ: HALO) during the se

Halozyme stock jumps 36% in a month as strong ENHANZE-driven royalties and recently raised 2026 guid

The GARP strategy helps investors gain exposure to stocks that have solid prospects and are trading

SAN DIEGO, Aug. 18, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme") tod

Major Commercialization Milestone Expands Sagtec's AI Robotics Platform into the Middle East and Est

Halozyme Therapeutics (HALO) is well positioned to outperform the market, as it exhibits above-avera

Here is how Halozyme Therapeutics (HALO) and Brookdale Senior Living (BKD) have performed compared t

3 health care stocks with high momentum could be overbought. Crinetics Pharmaceuticals (CRNX) has RS

Leerink Partners analyst David Risinger upgrades Halozyme Therapeutics (NASDAQ:HALO) from Market

TD Cowen analyst Brendan Smith maintains Halozyme Therapeutics (NASDAQ:HALO) with a Buy and raise

U.S. stocks rose, Nasdaq Composite up 1%. Natera Inc (NTRA) shares jump 20.5% after strong Q2 result

HALO's Q2 earnings and revenues surpass estimates, fueled by higher royalties and product sales. The

Citizens analyst Jason N. Butler maintains Halozyme Therapeutics (NASDAQ:HALO) with a Market Outp

Wells Fargo analyst Mohit Bansal maintains Halozyme Therapeutics (NASDAQ:HALO) with a Equal-Weigh

Wall Street analysts changed ratings & price targets for top stocks. Check out all changes inclu

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Halozyme Therapeutics (NASDAQ:HALO)

Halozyme Therapeutics NASDAQ: HALO reported record second-quarter revenue and raised its full-year o

Halozyme Therapeutics, Inc. (HALO) Q2 2026 Earnings Call Transcript

Although the revenue and EPS for Halozyme Therapeutics (HALO) give a sense of how its business perfo

Halozyme Therapeutics (HALO) came out with quarterly earnings of $2.28 per share, beating the Zacks

Halozyme Therapeutics (NASDAQ:HALO) reported quarterly earnings of $2.28 per share which beat the an

Halozyme Therapeutics (NASDAQ:HALO) raises FY2026 Adj EPS guidance from $7.75-$8.25 to $8.65-$9.00 v

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Halozyme Therapeutics (NASDAQ:HALO)

Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme" or the "Company") today announ

Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme" or the "Company") today confir

Morgan Stanley analyst Vikram Purohit maintains Halozyme Therapeutics (NASDAQ:HALO) with a Overwe

Halozyme Therapeutics (NASDAQ:HALO) affirms FY2026 Adj EPS guidance from $7.75-$8.25 to $7.75-$8.25

Halozyme Therapeutics (NASDAQ:HALO) reported quarterly earnings of $1.60 per share which beat the an

Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme" or the "Company") today announ

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Halozyme Therapeutics (NASDAQ:HALO)

Tech stocks recovered on Wednesday, led by a rally in battered software names, as the Nasdaq 100 jum

Agreement provides Takeda with exclusive access to ENHANZE® drug delivery technology for vedolizumab

Stocks were rising again midday Friday, putting Wall Street on pace for a fifth straight day of gain